34945.jpg
ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB
April 30, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, April 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
34945.jpg
ProQR Announces Annual Meeting of Shareholders
April 11, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, April 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
34945.jpg
ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology
April 10, 2018 07:00 ET | ProQR Therapeutics N.V.
Key Updates Dr. Peter A. Beal joins ProQR’s scientific advisory board, bringing with him tremendous experience in the field of RNA-based therapeutics, particularly in the area of RNA editing.As an...
logo_ProQR-150x150.png
ProQR to Present at Two Upcoming Conferences
April 03, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, April 03, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
logo_ProQR-150x150.png
ProQR to Present at Upcoming Investor Conference
March 05, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, March 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
logo_ProQR-150x150.png
ProQR to Present at Upcoming Scientific Meeting and Investor Conference
February 06, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Feb. 06, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
logo_ProQR-150x150.png
ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
November 13, 2017 07:00 ET | ProQR Therapeutics N.V.
Key Updates The first patient has received the first dose of QR-110 in the Phase 1/2 safety & efficacy clinical trial (PQ-110-001: NCT03140969) in children and adults with Leber’s congenital...
logo_ProQR-150x150.png
ProQR to Present at EuroTIDES Conference
October 31, 2017 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, The Netherlands, Oct. 31, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...